soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 semaglutide soul trial oral cardiovascular

These are typically self-guided and designed to support independent behavior change

Novo Nordisk holds patents on semaglutide that extend through approximately 2032, preventing generic manufacturers from producing equivalent versions

I filed a patent to use GLP-1 as an anxiolytic, but really, the mice were just sick patft.uspto.gov/netacgi/nph-Pa The CNS GLP-1 food intake #weightloss #obesity story has turned out to be far more scientifically interesting and clinically relevant than I first appreciated

Regular check-ups and blood tests can determine if there is a deficiency

(2015) GLP-1/glucagon co-agonist REE data, which remains the mechanistic anchor for every triagonist programme that followed [unverified]